Peritoneal Dialysis Watch — May 21, 2026

Welcome to your Peritoneal Dialysis Echo. This bi-weekly update covers 7 papers from the past 14 days.

[PAUSE]

The first paper addresses a fundamental question we face when initiating peritoneal dialysis: should we start with a standard, full-dose prescription, or is an 'incremental' lower-dose start a safe alternative? This comes from *Peritoneal Dialysis International*, reporting on data from the large, international PDOPPS study.

[PAUSE] The Study [PAUSE] Investigators analyzed data from over 13-hundred new PD patients across seven countries. They defined an 'incremental' start as prescribing fewer than four exchanges per day for CAPD, or using dry days or fewer than seven treatment days per week for APD. All other prescriptions were considered 'standard'. The primary outcome was transfer to hemodialysis.

[PAUSE] Results [PAUSE] Overall, about one-third of patients—37 percent—were started on incremental PD. The key finding is that there was no significant difference in the risk of transfer to hemodialysis between the groups. The hazard ratio for transfer in the incremental group was 0.87, with a 95 percent confidence interval of 0.68 to 1.12. Furthermore, there were no differences in peritonitis rates or overall mortality. The authors note that this is based on low-certainty evidence, but the findings are consistent across major outcomes.

[PAUSE] Discussion [PAUSE] This is one of the largest studies to date looking at incremental PD initiation. Its strength lies in its prospective design and international cohort, reflecting real-world practice. A limitation, as with any observational study, is the potential for confounding by indication—clinicians may have selected healthier patients or those with more residual kidney function for an incremental start. However, the analysis did adjust for many of these factors.

[PAUSE] Conclusions [PAUSE] The practice implication here is reassuring. For many patients, particularly those who are older or who retain significant residual kidney function, starting with a lower-dose, incremental PD prescription appears to be a safe strategy. It does not seem to increase the short-term risk of technique failure, infection, or death. This approach can reduce the treatment burden on the patient and may be a more gentle introduction to dialysis.

[PAUSE]

Moving to our second paper, we shift focus from clinical metrics to a critical patient-centered outcome: employment. Published in the *American Journal of Kidney Diseases*, this study compares employment status after starting peritoneal dialysis versus in-center hemodialysis.

[PAUSE] The Study [PAUSE] This was a large, national retrospective cohort study using the United States Renal Data System. Researchers looked at two groups of patients who started dialysis between 2013 and 2018. The first group included over 18,000 patients who were employed full-time at dialysis initiation. The second group included over 100,000 patients who were unemployed at initiation. The study used having employer-sponsored health insurance as a proxy for employment at the patient or household level. They then compared the likelihood of losing or gaining this insurance between patients on PD and those on in-center hemodialysis, or IHD.

[PAUSE] Results [PAUSE] The findings are quite stark. Compared to patients on PD, those on IHD were significantly more likely to lose their employer-sponsored insurance. The hazard ratio was 1.14 for IHD patients with a fistula, and 1.26 for those without a fistula. Conversely, when looking at the unemployed group, patients on IHD were significantly *less* likely to gain employer-sponsored insurance compared to their PD counterparts. The hazard ratios here were 0.59 for IHD with a fistula and 0.55 for IHD without one, indicating about a 40 to 45 percent lower chance of gaining insurance.

[PAUSE] Discussion [PAUSE] The major strength of this study is its massive sample size, providing robust statistical power. The primary limitation is its use of employer-sponsored insurance as a proxy for employment, which may not perfectly capture an individual's work status, though it is a reasonable surrogate in the United States healthcare system. There is also potential for residual confounding, as patient characteristics may influence both modality choice and employment potential.

[PAUSE] Conclusions [PAUSE] For practicing clinicians, this paper provides powerful data for patient counseling. When discussing modality choice with patients who are working or wish to work, we can now state with more confidence that peritoneal dialysis is associated with a higher probability of both maintaining and gaining employment compared to in-center hemodialysis. This is a crucial quality-of-life factor that should be a central part of the shared decision-making process.

[PAUSE]

Shifting gears to a thought-provoking perspective piece, our third paper from the *American Journal of Kidney Diseases* asks a bold question: Are we free to be in peritoneal dialysis… without Kt/V?

[PAUSE] The Argument [PAUSE] The authors, including Drs. Bargman and Perl, challenge the decades-long reliance on Kt/V urea as the primary marker of dialysis adequacy. They trace its history, highlighting the flawed assumptions that underpin its use in PD. These include its focus on urea as a single surrogate for all uremic toxins, the questionable equivalence between dialytic and residual kidney clearance, and the inherent difficulties in accurately measuring the volume of urea distribution.

[PAUSE] The Proposal [PAUSE] Instead of chasing a Kt/V target, the authors advocate for a paradigm shift towards a more holistic model of high-quality, person-centered care. They propose that we should focus on alternative quality metrics that are more directly meaningful to patients. These include preserving residual kidney function, optimizing nutrition and volume status, minimizing dialysis-related infections, and, critically, maintaining quality of life.

[PAUSE] Discussion [PAUSE] This is not a data-driven study but a powerful editorial synthesizing decades of evidence and clinical wisdom. Its strength is in its clear, logical deconstruction of a long-held dogma. It argues that the transformation of Kt/V from a research tool into a rigid quality metric may have inadvertently narrowed our focus, potentially at the expense of other important aspects of patient care.

[PAUSE] Conclusions [PAUSE] The practice implication is profound. This paper empowers clinicians to move beyond a "one-size-fits-all" numerical target. It encourages us to individualize care, focusing on the whole patient rather than just their urea clearance. While adequacy is important, this piece argues that it should be defined by a composite of meaningful outcomes, not a single, flawed lab value. It's a call to be freed from the constraints of Kt/V and to practice a more patient-centered art of medicine.

[PAUSE]

Our fourth paper offers a very practical solution to a common logistical challenge. From *Peritoneal Dialysis International*, this study looks at optimizing exit-site care for hospitalized PD patients.

[PAUSE] The Study [PAUSE] This was a quality improvement initiative conducted at a single center in Singapore. The clinical problem is that daily exit-site care for admitted PD patients is time-consuming for already-stretched nursing staff. The intervention was to switch from daily antibiotic dressing changes to a weekly chlorhexidine-impregnated sponge dressing. The goal was to see if this could reduce nursing time without increasing complications.

[PAUSE] Results [PAUSE] The results were impressive. The initiative included 211 hospitalized PD patients. Before the change, PD nurses spent a median of about 105 minutes per patient per month on exit-site care. After switching to the weekly chlorhexidine dressing, this plummeted to just 31 minutes—a 70 percent reduction. Over the study period, this saved an estimated 503 nursing hours. It was also cost-effective, with a net savings of over 53,000 Singapore dollars. Most importantly, not a single patient developed an exit-site infection, and no adverse events related to the new dressing were observed.

[PAUSE] Discussion [PAUSE] The strength of this study is its real-world, practical application. It presents a clear, actionable protocol with measured outcomes. As a single-center quality improvement project, it isn't a randomized controlled trial, and the follow-up was limited to the hospital stay, so long-term infection rates weren't assessed. However, for the specific context of in-hospital care, the findings are compelling.

[PAUSE] Conclusions [PAUSE] The take-home message is immediate and actionable for any hospital that manages PD patients. Adopting a weekly chlorhexidine-impregnated dressing for routine in-patient exit-site care appears to be a safe and highly effective way to save nursing time and healthcare resources. This is a simple change that can significantly improve workflow efficiency without compromising short-term patient safety.

[PAUSE]

Next, we look at a strategy for expanding access to home dialysis. Our fifth paper, also from *Peritoneal Dialysis International*, provides a retrospective review of an assisted peritoneal dialysis program in Alberta, Canada.

[PAUSE] The Study [PAUSE] Assisted PD, or aPD, is where a trained health care provider helps a patient perform their dialysis at home. It's designed for patients who have physical or cognitive barriers that prevent them from doing PD independently. This study reviewed the outcomes of 135 patients in an aPD program. Notably, the program initially used licensed practical nurses, or LPNs, but later switched to using health care aids, or HCAs, to provide the assistance. The primary outcome was the duration of time patients remained on aPD.

[PAUSE] Results [PAUSE] The average patient in the program was about 71 years old and remained on assisted PD for roughly one year. There was no difference in the time spent on PD between the group assisted by nurses and the group assisted by health care aids. The main reasons for exiting the program were death, at 30 percent, and switching to hemodialysis, at 27 percent. Critically, a significant portion of patients—21.5 percent, or about one in five—eventually transitioned from assisted PD to performing PD independently, staying on the modality for an additional 16 months on average. There were also no differences in peritonitis rates between the two care models.

[PAUSE] Discussion [PAUSE] This study provides valuable real-world data on the feasibility and success of an aPD program. Its strength is in describing a sustainable, long-term program and comparing two different staffing models. As a retrospective review, it has inherent limitations, but it offers a clear picture of who these programs serve and what their outcomes are.

[PAUSE] Conclusions [PAUSE] The clinical implication is clear: assisted PD is a vital tool for expanding home dialysis. It allows older patients and those with functional limitations to remain in their communities. The finding that a substantial minority of patients gain the skills and confidence to become independent is a major success. Furthermore, the data showing that health care aids can provide this care as safely and effectively as nurses suggests a more scalable and cost-effective model for developing these essential programs.

[PAUSE]

Our sixth paper explores the integration of modern technology into PD care. This pilot randomized controlled trial, published in *Peritoneal Dialysis International*, evaluates the engagement and usability of a mobile health app for PD patients.

[PAUSE] The Study [PAUSE] Investigators randomized 140 prevalent PD patients into two groups for six months. The intervention group used a mobile health app called "MyPD" in addition to their standard care. The control group received standard care only. The app was available for both CAPD and APD patients. The primary outcome was engagement, which was measured by the frequency of communication between the patient and the clinic, as well as the number of preemptive clinic visits.

[PAUSE] Results [PAUSE] The use of the MyPD app was associated with a significant increase in engagement. Over the six-month follow-up, the mean number of communications between the clinic and patients was 4.3 in the app group, compared to just 1.2 in the standard care group. This difference was statistically significant. The app also received a high usability score from patients, averaging 6.5 out of a maximum of 7. While the study wasn't powered for clinical outcomes, there were no significant differences in peritonitis, hospitalizations, or emergency room visits between the groups.

[PAUSE] Discussion [PAUSE] As a pilot RCT, this study's strength is its randomized design, which reduces bias in assessing the app's effect on communication. The main limitation is that it's a pilot study, so it can't tell us if this increased engagement translates into better hard outcomes like reduced hospitalizations or technique failure. It demonstrates a change in process, but not yet a definitive change in outcome.

[PAUSE] Conclusions [PAUSE] This study provides encouraging evidence for the role of digital health in PD. Mobile apps appear to be a highly usable and effective tool for increasing communication between patients and their care teams. This enhanced connection can facilitate more proactive management, allowing clinicians to intervene before a problem escalates. While larger studies are needed to confirm an impact on clinical endpoints, integrating such tools into routine care seems a promising way to improve patient engagement and monitoring.

[PAUSE]

Finally, our seventh paper is a comprehensive review from *Peritoneal Dialysis International* that synthesizes our understanding of a common and critical event: transitions to and from peritoneal dialysis.

[PAUSE] The Review [PAUSE] The authors, Desbiens and Nadeau-Fredette, provide a practical framework for managing modality transitions, which are extremely common in the life of a PD patient. They cover transfers from PD to facility hemodialysis, temporary interruptions, and the transition from other modalities to PD. The review highlights that these transitions are not just logistical hurdles; they are frequently associated with hospitalizations, increased mortality, and higher healthcare costs.

[PAUSE] Key Concepts [PAUSE] A central theme is that some transfers are unavoidable and should be anticipated as part of a patient's "dialysis life plan." Rather than viewing a switch to hemodialysis as a failure of PD, it should be seen as a predictable step in the journey for many patients. The review discusses risk factors for technique failure and strategies to optimize outcomes during a transition, such as timely permanent access placement and coordinated care. It also champions the concept of an "integrated home dialysis" paradigm, where the preferred transition from PD is not to in-center HD, but to home hemodialysis, allowing the patient to maintain the independence and flexibility of a home therapy.

[PAUSE] Discussion [PAUSE] As a review article, its strength is not in new data, but in its synthesis of existing evidence into a clinically useful guide. It consolidates information on epidemiology, risk factors, and best practices into one place, serving as an excellent educational resource.

[PAUSE] Conclusions [PAUSE] The practice implication is to be proactive, not reactive. We should educate our PD patients from the beginning that a future transition to another modality is possible, or even likely. This involves planning ahead for access, managing patient expectations, and importantly, discussing home hemodialysis as a primary option after PD. By embedding transition planning into routine care, we can make these high-risk events safer and less disruptive for our patients.

[PAUSE]

Synthesizing this period's papers, a few clear themes emerge. There's a strong push towards more patient-centered and individualized care, moving beyond rigid metrics like Kt/V to focus on outcomes like employment and quality of life. We also see a focus on expanding access to home therapies through innovative models like assisted PD. Technology is playing a larger role, with mobile apps enhancing patient engagement and new dressing protocols improving efficiency. Finally, there's a growing recognition of the need for proactive lifecycle management, planning for modality transitions as an integral part of the patient's entire dialysis journey.

[PAUSE]

That's your Peritoneal Dialysis update for this period. Until next time, stay evidence-based.